Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.34 USD
Change Today +0.04 / 0.55%
Volume 453.3K
As of 1:26 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Snapshot

Open
$7.33
Previous Close
$7.30
Day High
$7.52
Day Low
$7.24
52 Week High
01/14/15 - $9.60
52 Week Low
08/4/14 - $4.19
Market Cap
460.8M
Average Volume 10 Days
506.7K
EPS TTM
$-0.79
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENOPORT INC (XNPT)

xenoport inc (XNPT) Related Businessweek News

No Related Businessweek News Found

xenoport inc (XNPT) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase I clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is in Phase III clinical trials used for the treatment of spasticity in multiple sclerosis; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease has completed Phase II clinical trials. The company has a license agreement with Indivior PLC to develop and commercialize pharmaceutical products containing arbaclofen placarbil; license agreement with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan; and collaboration agreement with Glaxo Group Limited to develop and commercialize gabapentin enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

152 Employees
Last Reported Date: 02/27/15
Founded in 1999

xenoport inc (XNPT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $500.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $439.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $364.2K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $346.1K
Compensation as of Fiscal Year 2014.

xenoport inc (XNPT) Key Developments

Xenoport, Inc. Reports New Expert Recommendations for the Prevention and Treatment of Augmentation in Patients Suffering from Restless Legs Syndrome

XenoPort, Inc. reported that new expert recommendations for the prevention and treatment of augmentation in patients suffering from restless legs syndrome (RLS) list gabapentin enacarbil as a first-line therapy with a lower risk of developing augmentation. In addition, gabapentin enacarbil is listed as an alternative treatment for the management of patients suffering from augmentation who were previously treated with dopaminergic medication. RLS augmentation is an insidious worsening of RLS symptoms that can occur after treatment of RLS with dopaminergic medication. The recommendations were created by the combined Task Force from the International RLS Study Group (IRLSSG), the European RLS Study Group (EURLSSG) and the RLS Foundation. HORIZANT® (gabapentin enacarbil) Extended-Release Tablets is the only non-dopaminergic medication and the only alpha-2-delta calcium-channel ligand class medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe primary RLS in adults.

Xenoport, Inc. to Present New Pooled Data Analyses on Horizant at the 2015 Sleep Annual Meeting

Xenoport, Inc. announced that pooled data analyses for HORIZANT (gabapentin enacarbil) Extended-Release Tablets, will be presented at the upcoming 29th Associated Professional Sleep Societies (APSS) annual SLEEP meeting in Seattle. The presentations include: Association Between Pain and Symptoms of Restless Legs Syndrome (RLS) in adults with moderate-to-severe. Primary RLS in a Combined Treatment Population: Pooled Analyses From 3 Randomized Controlled Trials. Poster #253, June 10, 205, Exhibit Hall 4AB. The Effect of Gabapentin Enacarbil on Pain Outcomes and Restless Legs Syndrome Symptoms in adults with moderate-to-severe primary RLS: Pooled Analyses From 3 Randomized, Controlled Trials. Poster #256, June 10, 2015, Exhibit Hall 4AB.

Xenoport, Inc. Approves Amendments to Amended and Restated Certificate of Incorporation

Xenoport, Inc. announced at the AGM held on May 19, 2015, it has approved amendments to the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock and approved amendments to the charter and company's amended and restated bylaws to eliminate the supermajority voting requirement for amendments to XenoPort's amended and restated bylaws.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $7.34 USD +0.04

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $6.52 USD +0.07
Alkermes PLC $69.81 USD -0.21
Bristol-Myers Squibb Co $64.85 USD -0.79
Skyepharma PLC 282.00 GBp +2.00
Valeant Pharmaceuticals International Inc C$335.61 CAD +4.75
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit www.xenoport.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.